Blueprint Medicines Corporation (BPMC)

Market Cap	6.91B
Revenue (ttm)	282.21M
Net Income (ttm)	-288.29M
Shares Out	62.62M
EPS (ttm)	-4.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	477,258
Open	108.93
Previous Close	109.18
Day's Range	107.46 - 110.46
52-Week Range	43.89 - 111.42
Beta	0.70
Analysts	Buy
Price Target	110.20 (-0.15%)
Earnings Date	Jul 31, 2024

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2015
• Employees: 655
• Stock Exchange: NASDAQ
• Ticker Symbol: BPMC

Financial Performance

In 2023, BPMC's revenue was $249.38 million, an increase of 22.22% compared to the previous year's $204.04 million. Losses were -$506.98 million, -9.06% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $110.2, which is a decrease of -0.15% from the latest price.

Price Target

$110.2

(-0.15% downside)

Analyst Consensus: Buy